niacin has been researched along with Kidney Diseases in 20 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268)." | 5.14 | Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. ( Bostom, AG; Hanlon, WA; Kuznetsova, O; Maccubbin, D; Tipping, D, 2010) |
| "Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders." | 2.77 | Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. ( Ahmadi, F; Khatami, MR; Lessan-Pezeshki, M; Shamekhi, F, 2012) |
| " Dose recommendations for these patients are not available because pharmacokinetic data are missing." | 1.37 | Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ( Bode-Böger, SM; Luley, C; Martens-Lobenhoffer, J; Reiche, I; Tröger, U; Westphal, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (45.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, HJ | 1 |
| McCullough, PA | 1 |
| Yasmeen, G | 1 |
| Dawani, ML | 1 |
| Mahboob, T | 1 |
| Bostom, AG | 2 |
| Maccubbin, D | 1 |
| Tipping, D | 1 |
| Kuznetsova, O | 1 |
| Hanlon, WA | 1 |
| Moorthi, RN | 1 |
| Moe, SM | 1 |
| Drüeke, T | 1 |
| Uhlig, K | 1 |
| Reiche, I | 1 |
| Westphal, S | 1 |
| Martens-Lobenhoffer, J | 1 |
| Tröger, U | 1 |
| Luley, C | 1 |
| Bode-Böger, SM | 1 |
| Ahmadi, F | 1 |
| Shamekhi, F | 1 |
| Lessan-Pezeshki, M | 1 |
| Khatami, MR | 1 |
| KNICK, B | 1 |
| MARZETTI, L | 2 |
| BENAGIANO, G | 1 |
| MIGLIAU, G | 1 |
| RENGO, F | 1 |
| FARINA, A | 1 |
| GRAZIANI, B | 1 |
| Kronenberg, F | 2 |
| Kwan, BC | 1 |
| Beddhu, S | 1 |
| Cheung, AK | 1 |
| Restrepo Valencia, CA | 1 |
| Cruz, J | 1 |
| Higashino, K | 1 |
| Moriwaki, Y | 1 |
| Cayen, MN | 1 |
| Parker, F | 1 |
| MILNE, MD | 2 |
| SRIKANTIA, SG | 1 |
| VENKATACHALAM, PS | 1 |
| REDDY, V | 1 |
6 reviews available for niacin and Kidney Diseases
| Article | Year |
|---|---|
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer P | 2014 |
Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Kidney Diseases; Lipoprotein(a); Niacin; Polymorphism, | 2004 |
Lipoprotein metabolism and lipid management in chronic kidney disease.
Topics: Antioxidants; Cardiovascular Diseases; Chronic Disease; Dyslipidemias; Humans; Hydroxymethylglutaryl | 2007 |
[Pharmacological agents affecting uric acid metabolism].
Topics: Allopurinol; Diuretics; Fructose; Gout; Gout Suppressants; Humans; Inosine; Kidney Diseases; Niacin; | 1996 |
Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man.
Topics: Animals; Binding Sites; Biological Availability; Biotransformation; Clofibrate; Drug Interactions; H | 1985 |
[RENAL TUBULAR DISEASES, WITH SPECIAL REFERENCE TO AMINOACIDURIA].
Topics: Cystinosis; Cystinuria; Galactosemias; Genetics, Medical; Glycine; Hepatolenticular Degeneration; Hu | 1964 |
3 trials available for niacin and Kidney Diseases
| Article | Year |
|---|---|
Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease.
Topics: Adult; Atorvastatin; Biomarkers; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combin | 2015 |
Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
Topics: Aged; Biomarkers; Calcium; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Drug T | 2010 |
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Calcium; Chelating Agents; Female; Humans; Hyperphosp | 2012 |
11 other studies available for niacin and Kidney Diseases
| Article | Year |
|---|---|
Binder blinders-niacin of omission?
Topics: Animals; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Humans; Hyperphosphatem | 2010 |
All research does not a guideline make!
Topics: Biomedical Research; Bone Diseases; Chronic Disease; Humans; Kidney Diseases; Niacin; Phosphorus Met | 2010 |
Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Topics: Aged; Chronic Disease; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2011 |
[Nicotinic acid therapy of anuric disorders in acute & chronic renal insufficiency].
Topics: Acute Kidney Injury; Anuria; Humans; Kidney Diseases; Niacin; Nicotinic Acids; Renal Insufficiency, | 1959 |
[POSSIBILITIES AND ADVANTAGES OF FIBRINOLYTIC DRUGS IN THERAPY OF KIDNEY DISEASE IN PREGNANCY].
Topics: Blood Coagulation Disorders; Drug Therapy; Female; Fibrinolysis; Fibrinolytic Agents; Humans; Kidney | 1964 |
[INTRAVASCULAR COAGULATION AND FIBRINOLYSIS. EXPERIMENTAL CONTRIBUTION TO THE STUDY OF TREATMENT OF KIDNEY DISEASE IN PREGNANCY].
Topics: Animals; Blood Coagulation; Blood Coagulation Disorders; Female; Fibrinolysis; Humans; Kidney; Kidne | 1964 |
[EFFECT OF THE ADMINISTRATION OF NICOTINIC ACID BY INTRAVENOUS ROUTE ON RENAL CIRCULATION AND FUNCTION].
Topics: Heart Diseases; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Niacin; Pharmacology; Renal | 1964 |
[Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
Topics: Chronic Disease; Female; Humans; Hyperlipidemias; Hyperphosphatemia; Hypolipidemic Agents; Kidney Di | 2008 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |
DISORDERS OF AMINO-ACID TRANSPORT.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Cystinosis; Cystinuria; Dog Diseases; Dogs; Kidney Di | 1964 |
CLINICAL AND BIOCHEMICAL FEATURES OF A CASE OF HARTNUP DISEASE.
Topics: Biochemical Phenomena; Biochemistry; Child; Genetics, Medical; Hartnup Disease; Humans; Indican; Ind | 1964 |